Trial Profile
A phase I open-label, two period, single center study to assess the effect of 600 mg daily oral dose of rifampin (CYP3A4 inducer) on the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Rifampicin
- Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Malignant melanoma; Tuberculosis
- Focus Pharmacokinetics
- Sponsors Novartis